Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 616-629
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Current status and future perspectives in targeted therapy of NPM1-mutated AML
Roberta Ranieri, Giulia Pianigiani, Sofia Sciabolacci, et al.
Leukemia (2022) Vol. 36, Iss. 10, pp. 2351-2367
Open Access | Times Cited: 68
Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia
Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 21
Open Access | Times Cited: 66
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Yasmin Abaza, Amer M. Zeidan
Cells (2022) Vol. 11, Iss. 14, pp. 2249-2249
Open Access | Times Cited: 44
Escape from T-cell–targeting immunotherapies in acute myeloid leukemia
Jayakumar Vadakekolathu, Sergio Rutella
Blood (2023) Vol. 143, Iss. 26, pp. 2689-2700
Open Access | Times Cited: 32
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
Cecilia Restelli, Marco Ruella, Luca Paruzzo, et al.
Blood Cancer Discovery (2024) Vol. 5, Iss. 4, pp. 234-248
Closed Access | Times Cited: 10
CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia
Francesco Mazziotta, Luca Biavati, Joseph Rimando, et al.
Blood (2024) Vol. 144, Iss. 11, pp. 1168-1182
Closed Access | Times Cited: 9
TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Mithun Vinod Shah, Daniel A. Arber, Devendra Hiwase
American Journal of Hematology (2025)
Open Access | Times Cited: 1
An Overview of Targeted Therapies in Acute Myeloid Leukemia
Sven Turkalj, Felix A. Radtke, Paresh Vyas
HemaSphere (2023) Vol. 7, Iss. 6, pp. e914-e914
Open Access | Times Cited: 22
Maintenance therapy in acute myeloid leukemia: advances and controversies
Jayastu Senapati, Tapan M. Kadia, Farhad Ravandi
Haematologica (2023)
Open Access | Times Cited: 17
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Poonam N. Desai, Bofei Wang, André Fonseca, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 7, pp. 1011-1028
Open Access | Times Cited: 17
Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies
Wioletta Olejarz, Karol Sadowski, Daniel Szulczyk, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7743-7743
Open Access | Times Cited: 8
What have we learned about TP53-mutated acute myeloid leukemia?
Moazzam Shahzad, Muhammad Kashif Amin, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Immune checkpoint blockade in hematological malignancies: current state and future potential
Prateek Pophali, Juan Carlos Varela, Jacalyn Rosenblatt
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
Eric M Granowicz, Brian A. Jonas
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 423-436
Open Access | Times Cited: 26
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges
Ying Chen, Jishi Wang, Fengqi Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
Recent advances in CAR‐T cell therapy for acute myeloid leukaemia
C. Gao, Xin Li, Yao Xu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 9
Open Access | Times Cited: 5
A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia
Başak Aru, Cemil Pehlivanoğlu, Zeynep Dal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Progress of research on PD-1/PD-L1 in leukemia
Huizhen Cao, Tianyu Wu, Xue Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Novel immunotherapies in the treatment of AML: is there hope?
Marion Subklewe, Veit Bücklein, David A. Sallman, et al.
Hematology (2023) Vol. 2023, Iss. 1, pp. 691-701
Closed Access | Times Cited: 10
Bone marrow immune cells and drug resistance in acute myeloid leukemia
Miao Zhang, You Yang, Jing Liu, et al.
Experimental Biology and Medicine (2025) Vol. 250
Open Access
The Emerging Role of CD8+ T Cells in Shaping Treatment Outcomes of Patients with MDS and AML
Athanasios Tasis, Theodoros Spyropoulos, Ioannis Mitroulis
Cancers (2025) Vol. 17, Iss. 5, pp. 749-749
Open Access
Meta-analysis of Therapeutic Approaches in Acute Myeloid Leukemia
Zaheer Qureshi, Abdur Jamil, Faryal Altaf, et al.
American Journal of Clinical Oncology (2025)
Closed Access
Therapeutic Hurdles in Acute Myeloid Leukemia: Leukemic Stem Cells, Inflammation and Immune Dysfunction
Bofei Wang, Patrick K. Reville, Hussein A. Abbas
Current Opinion in Pharmacology (2025), pp. 102526-102526
Closed Access
Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia
Hui-Sheng Zhou, Yong-Feng Su, Jun Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment
Yasmina Serroukh, Josée Hébert, Lambert Busque, et al.
Blood Reviews (2022) Vol. 57, pp. 100991-100991
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top